Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death

Autor: Gisby, J, Clarke, C, Medjeral-Thomas, N, Malik, T, Papadaki, A, Mortimer, P, Buang, N, Lewis, S, Pereira, M, Toulza, F, Fagnano, E, Mawhin, M-A, Dutton, E, Tapeng, L, Kirk, P, Behmoaras, J, Sandhu, E, McAdoo, S, Prendecki, M, Pickering, M, Botto, M, Willicombe, M, Thomas, D, Peters, J

End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19. We performed dense serial blood sampling in hospitalised and non-hospitalised ESKD patients with COVID-19 (n=256 samples from 55 patients) and used Olink immunoassays to me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::1ae212879eae70d268c7786334eb5fff
http://hdl.handle.net/10044/1/83799

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017)

Autor: Cheadle, E. J., Lipowska-Bhalla, G., Dovedi, S. J., Fagnano, E., Klein, C., Honeychurch, J., Illidge, T. M.

Publikováno v: Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J & Illidge, T M 2017, ' A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017) ' Leukemia, vol 31, no. 10, pp. 2278-2278 . DOI: 10.1038/leu.2016.352
Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J & Illidge, T M 2017, ' A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells (vol 31, pg 1611, 2017) ', Leukemia, vol. 31, no. 10, pp. 2278-2278 . https://doi.org/10.1038/leu.2016.352

Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c1346ea34ddd57b017f69a04f796678f
https://doi.org/10.1038/leu.2016.352

910 - A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model

Autor: Cheadle, E., Lipowska-Bhalla, G., Fagnano, E., Klein, C., Dovedi, S., Honeychurch, J., Illidge, T.

Publikováno v: In European Journal of Cancer July 2016 61 Supplement 1:S211-S211

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.